Introduction to the molecular imaging;Introducción a la imagen molecular

Revista Espanola de Medicina Nuclear

Volumn 25, Issue 6, 2006, Pages 394-409

  Aparici, C Mari ^a,b,c,d  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTORADIOGRAPHY; BIOLUMINESCENCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; FLUORESCENCE; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; REVIEW;

EID: 33846277630     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13095176     Document Type: Article

References (71)

1. Weissleder R, Mahmood U. Molecular Imaging. Radiology. 2001;219:316-33.
2. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes & development. 2003;17:545-80.
3. Wagenaar DJ, Weissleder R, Hengerer A. Glossary of molecular imaging terminology. Acad Radiol. 2001;8:409-20.
4. Ronald G. Blasberg. Molecular Imaging and Cancer. Molecular Cancer Therapeutics. 2003;2:335-43.
5. Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001;219:316-33.
6. Strijckmans K. The isochronous cyclotron: principles and recent developments. Comput Med Imaging Graph. 2001;25:69-78.
7. Rosenthal N. Molecular medicine. Recognizing DNA. N Engl J Med. 1995;333:925-7.
8. Contag CH, Ross BD. It's Not Just About Anatomy: In Vivo bioluminescence Imaging as an Eyepiece into Biology. Journal of magnetic resonance imaging. 2002;16:378-87.
9. Spibey CA, Jackson P, Herick K. A unique charge-coupled device/xenon arc lamp based imaging system for the accurate detection and quantitation of multicolour fluorescence. Electrophoresis. 2001;22:829-36.
10. Vooijs M, Jonkers J, Lyons S, Berns A. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res. 2002;62:1862-7.
11. Contag CH, Contag PR, Mullins JI, Spilman SD, Stevenson DK, Benaron DA. Photonic detection of bacterial pathogens in living hosts. Mol Microbiol. 1995;18:593-603.
12. Li S, Zhang Q, Jiang H. Two-dimensional bioluminescence tomography: numerical simulations and phantom experiments. Appl Opt. 2006;45:3390-4.
13. Dehghani H, Davis SC, Jiang S, Pogue BW, Paulsen KD, Patterson MS. Spectrally resolved bioluminescence optical tomography. Opt Lett. 2006;31:365-7.
14. Cong W, Wang G. Boundary integral method for bioluminescence tomography. J Biomed Opt. 2006;11:20503.
15. Lippincott-Schwartz J, Snapp E, Kenworthy A. Studying protein dynamics in living cells. Nat Rev Mol Cell Biol. 2001;2: 444-56.
16. Lewin JS, Merkle EM, Duerk JL, Tarr RW. Low-flow vascular malformations in the head and neck: safety and feasibility of MR imaging-guided percutaneous sclerotherapy-preliminary experience with 14 procedures in three patients. Radiology. 1999; 211:566-70.
17. Shaharabany M, Abramovitch R, Kushnir T, Tsarfaty G, Ravid-Megido M, Horev J, et al. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res. 2001;61:4873-8.
18. Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry. 1997;154:116-8.
19. Moore CC, Lugo-Olivieri CH, McVeigh ER, Zerhouni EA. Three-dimensional systolic strain patterns in the normal human left ventricle: characterization with tagged MR imaging. Radiology. 2000;214:453-66.
20. Weissleder R, Cheng HC, Bogdanova A, Bogdanov A Jr. Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging. 1997;7:258-63.
21. Turetschek K, Roberts TP, Floyd E, Preda A, Novikov V, Shames DM, et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging. 2001;13:882-8.
22. Jackson GD, Opdam HI. Ictal fMRI: methods and models. Adv Neurol. 2000;83:203-11.
23. Chatham JC, Blackband SJ. Nuclear magnetic resonance spectroscopy and imaging in animal research. ILAR J. 2001;42: 189-208.
24. Phelps ME. PET: a biological imaging technique. Neurochem Res. 1991;16:929-40.
25. Castillo M, Kwock L, Mukherji SK. Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol. 1996;17: 1-15.
26. Kohl G. The evolution and state-of-the-art principles of multislice computed tomography. Proc Am Thorac Soc. 2005;2: 470-6, 499-500.
27. Turnbull DH, Lum PK, Kerr AT, Foster FS. Simulation of B-scan images from two-dimensional transducer arrays: Part I-Methods and quantitative contrast measurements. Ultrason Imaging. 1992;14:323-43.
28. Turnbull DH, Foster FS. Simulation of B-scan images from two-dimensional transducer arrays: Part II-Comparisons between linear and two-dimensional phased arrays. Ultrason Imaging. 1992;14:344-53.
29. Turnbull DH, Bloomfield TS, Baldwin HS, Foster FS, Joyner AL. Ultrasound backscatter microscope analysis of early mouse embryonic brain development. Proc Natl Acad Sci USA. 1995; 92:2239-43.
30. Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular imaging and therapy. Prog Cardiovasc Dis. 2001; 44:13-31.
31. Hasegawa BH, Iwata K, Wong KH, Wu MC, Da Silva AJ, Tang HR, et al. Dual-modality imaging of function and physiology. Acad Radiol. 2002;9:1305-21.
32. Cherry SR. Multimodality In Vivo Imaging Systems: Twice the Power or Double the Trouble? Annu Rev Biomed Eng. 2006.
33. Chen X. Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem. 2006;6:227-34.
34. Doubrovin M, Serganova I, Mayer-Kuckuk P, Ponomarev V, Blasberg RG. Multimodality in vivo molecular-genetic imaging. Bioconjug Chem. 2004;15:1376-88.
35. Sun EY, Josephson L, Kelly KA, Weissleder R. Development of nanoparticle libraries for biosensing. Bioconjug Chem. 2006; 17:109-13.
36. Gambhir SS. Using radiolabeled DNA as an imaging agent to recognize protein targets. J Nucl Med. 2006;47:557-8.
37. Penuelas I, Haberkorn U, Yaghoubi S, Gambhir SS. Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging. 2005;32 Suppl 2:8384-403.
38. Wang Y, Iyer M, Annala AJ, Chappell S, Mauro V, Gambhir SS. Noninvasive monitoring of target gene expression by imaging reporter gene expression in living animals using improved bicistronic vectors. J Nucl Med. 2005;46:667-74.
39. Bogdanov A Jr, Weissleder R. The development of in vivo imaging systems to study gene expression. Trends Biotechnol. 1998; 16:5-10.
40. Bremer C, Weissleder R. In vivo imaging of gene expression. Acad Radiol. 2001;8:15-23.
41. Ishikawa TO, Jain NK, Taketo MM, Herschman HR. Imaging cyclooxygenase-2 (Cox-2) gene expression in living animals with a luciferase knock-in reporter gene. Mol Imaging Biol. 2006;8:171-87.
42. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T, et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia. 2000;2:118-38.
43. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, et al. 1241-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 2003;44:1962-9.
44. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005;65:622-31.
45. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med. 1999;40:184-91.
46. Blankenberg F, Mari C, Strauss HW. Imaging cell death in vivo. Q J Nucl Med. 2003;47:337-48.
47. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 1998;95:6349-54.
48. Blankenberg F, Ohtsuki K, Strauss HW. Dying a thousand deaths. Radionuclide imaging of apoptosis. Q J Nucl Med. 1999; 43:170-6.
49. Ohtsuki K, Akashi K, Aoka Y, Blankenberg FG, Kopiwoda S, Tait JF, et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med. 1999;26:1251-8.
50. Takei T, Kuge Y, Zhao S, Sato M, Strauss HW, Blankenberg FG, et al. Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation. J Nucl Med. 2005;46:794-9.
51. Mandl SJ, Mari C, Edinger M, Negrin RS, Tait JF, Contag CH, et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging. 2004;3:1-8.
52. Mari C, Karabiyikoglu M, Goris ML, Tait JF, Yenari MA, Blankenberg FG. Detection of focal hypoxic-ischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/reperfusion using radiolabeled annexin V. Eur J Nucl Med Mol Imaging. 2004;31:733-9.
53. Taki J, Higuchi T, Kawashima A, Tait JF, Kinuya S, Muramori A, et al. Detection of cardiomyocyte death in a rat model of ischemia and reperfusion using 99mTc-labeled annexin V. J Nucl Med. 2004;45:1536-41.
54. Kown MH, van der Steenhoven TJ, Jahncke CL, Mari C, Lijkwan MA, Koransky ML, et al. Zinc chloride-mediated reduction of apoptosis as an adjunct immunosuppressive modality in cardiac transplantation. J Heart Lung Transplant. 2002;21:360-5.
55. Blankenberg FG, Mari C, Strauss HW. Development of radio contrast agents for vascular imaging: progress to date. Am J Cardiovasc Drugs. 2002;2:357-65.
56. Shibuya M. Vascular Endothelial Growth Factor (VEGF)-Receptor2: Its Biological Functions, Major Signaling Pathway, and Specific Ligand VEGF-E. Endothelium. 2006;13:63-9.
57. Cudmore M, Ahmad S, Al-Ani B, Hewett P, Ahmed S, Ahmed A. VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways. Biochem Biophys Res Commun; 2006.
58. Osada S, Imai H, Tomita H, Tokuyma Y, Okumura N, Sakashita F, et al. Vascular endothelial growth factor protects hepatoma cells against oxidative stress-induced cell death. J Gastroenterol Hepatol. 2006;21:988-93.
59. Uyttersprot N, Pelgrims N, Carrasco N, Gervy C, Maenhaut C, Dumont JE, et al. Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na + /I-symporter mRNAs in dog thyroid. Mol Cell Endocrinol. 1997;131:195-203.
60. Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N. Thyroid Na + /I-symporter. Mechanism, stoichiometry, and specificity. J Biol Chem. 1997;272:27230-8.
61. Levy O, De la Vieja A, Carrasco N. The Na + /I-symporter (NIS): recent advances. J Bioenerg Biomembr. 1998;30:195-206.
62. Riedel C, Dohan O, De la Vieja A, Ginter CS, Carrasco N. Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer. Trends Biochem Sci. 2001; 26:490-6.
63. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24: 48-77.
64. Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003;88:1880-8.
65. Dadachova E, Carrasco N. The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med. 2004;34:23-31.
66. Dohan O, De la Vieja A, Carrasco N. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells. Mol Endocrinol. 2006;20:1121-37.
67. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24-35.
68. Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, et al. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol. 2003;5: 404-17.
69. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12: 584-95.
70. Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res. 2004;1025:98-105.
71. Newberg AB, Wintering NA, Plossl K, Hochold J, Stabin MG, Watson M, et al. Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. J Nucl Med. 2006;47:748-54.